News

Deal Announcements

BioAtla Bags Major New Backer

Tuesday, January 12, 2016 5:40:00 AM PDT | VentureDeal
   San Diego, California  --  Biotechnology company BioAtla has received $45 million in new venture capital debt and equity.

BioAtla is developing antibody therapeutics using Conditionally Active Biologics (CABs).

The company recently entered into a strategic license and option agreement with pharmaceutical giant Pfizer.

Global BIO Impact Fund made the investment.

The fund will "share in the risks and the potential returns of BioAtla's first four CAB candidates."

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1